**Core Concept**
The patient is likely suffering from syphilis, a chronic bacterial infection caused by Treponema pallidum. Monitoring the response to treatment involves assessing the serological markers of the disease.

**Why the Correct Answer is Right**
The correct answer is based on the understanding that syphilis is characterized by a biphasic serological response. Initially, the patient develops a non-treponemal test (RPR or VDRL) which becomes positive, followed by a treponemal test (TPHA or FTA-ABS) which becomes positive later. Monitoring the response to treatment involves checking for a decline in the non-treponemal test titers, indicating a successful treatment. This is because the non-treponemal tests measure the antibodies against the host's response to the treponemal infection, which decrease as the disease is treated.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not relevant to monitoring the response to treatment in syphilis.
* **Option B:** This option does not apply to syphilis treatment response monitoring.
* **Option C:** This option is not a valid test for monitoring the response to treatment in syphilis.

**Clinical Pearl / High-Yield Fact**
It's essential to note that a non-reactive treponemal test (e.g., TPHA or FTA-ABS) in a patient with a known history of syphilis can indicate a false-negative result, and a repeat test should be performed after 3-6 months to confirm the diagnosis.

**Correct Answer:** C. RPR (Rapid Plasma Reagin) or VDRL (Venereal Disease Research Laboratory) titers.